I would describe MAB therapies and any other that are designed to reduce virtual load as replacement therapy for vaccines. Get the vaccines and these therapies will hardly be used.
Drugs designed to stop inflammation is the only competition Mesoblast has. Unfortunately although many seem to help short term, long-term survival benefit is very marginal .
We all know the benefit that Remestemcell-L provides when combined with Dexamethasone and the majority of ICU ARDS patients would now be getting this.
Focus has been on vaccines and treatments for the masses, this will change as those making decisions become aware that the ICUs are full with patients that have been vaccinated. MSB is ready.
New Covid 19 treatment, page-10
-
- There are more pages in this discussion • 435 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.01 |
Change
0.030(3.06%) |
Mkt cap ! $1.153B | |||
| Open | High | Low | Value | Volume |
| $1.01 | $1.04 | 99.0¢ | $5.111M | 5.050M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 211966 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.02 | 136540 | 9 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |